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Abstract
 Hypoxia-inducible factor (HIF) transcription factors are wellBackground:
known to control the transcriptional response to hypoxia. Given the importance
of cellular response to hypoxia, a number of pharmacological agents to
interfere with this pathway have been developed and entered pre-clinical or
clinical trial phases. However, how similar or divergent the transcriptional
response elicited by different points of interference in cells is currently
unknown.
We performed RNA-sequencing to analyse the similarities andMethods: 
differences of transcriptional response in HeLa cells treated with hypoxia or
chemical agents that stabilise HIF by inhibiting components of the hypoxia
signalling pathway – prolyl hydroxylase (PHD) inhibitor or von Hippel–Lindau
(VHL) inhibitor.
This analysis revealed that hypoxia produces the highest changes inResults: 
gene transcription, with activation and repression of genes being in large
numbers. Treatment with the PHD inhibitor IOX2 or the VHL inhibitor VH032 led
mostly to gene activation, majorly via a HIF-dependent manner. These results
were also confirmed by qRT-PCR using more specific and/or efficient inhibitors,
FG-4592 (PHDs) and VH298 (VHL).
PHD inhibition and VHL inhibition mimic gene activationConclusion: 
promoted by hypoxia via a HIF-dependent manner. However, gene repression
is mostly associated with the hypoxia response and not common to the
response elicited by inhibitors of the pathway.
Keywords
Hypoxia, HIF, PHDs, VHL, FG-4592, IOX2, VH298, RNA-seq.
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Introduction
Hypoxia, or reduced oxygen availability, is associated with 
many physiological processes, such as embryonic development 
and high altitude living but also pathological processes such as 
stroke and cancer (Rocha, 2007). A major regulator of oxygen 
sensing and response is the family of transcription factors called 
hypoxia-inducible factors (HIFs). HIFs are activated in response 
to hypoxia to initiate a transcriptional program, and ultimately 
restore oxygen homeostasis and promote cell survival (Kenneth 
& Rocha, 2008). HIFs are heterodimeric transcription factors 
composed of a constitutively stable β-subunit (HIF-1β) and an 
oxygen-labile α-subunit (HIF-α) (Kenneth & Rocha, 2008). HIF-α 
is encoded by three different genes: HIF-1α, HIF-2α and HIF-3α, 
and each could function differently depending on tissue localisa-
tion (Kenneth & Rocha, 2008). HIF-α is rapidly degraded by the 
proteasome under normal oxygen levels as prolyl hydroxylase 
domain (PHD) enzymes and factor inhibiting HIF (FIH) utilise 
molecular oxygen as a co-factor, in addition to Fe2+ and 2-oxoglu-
tarate, to hydroxylate HIF-α proteins (Kenneth & Rocha, 2008). 
Hydroxylated prolines on HIF-α create a recognition site with a 
substantial increase in affinity over the parent protein containing 
unmodified proline, for the E3 ubiquitin ligase, von Hippel–Lindau 
(VHL) tumour suppressor that poly-ubiquitinates HIF-α, target-
ing the protein for proteasomal degradation (Hon et al., 2002). In 
hypoxia, however, HIF-α evades degradation and is stabilised as a 
result of insufficient oxygen molecules for PHDs to function. The 
accumulated HIF-α dimerises with HIF-1β and binds to the consen-
sus motif hypoxia response elements (HREs) of HIF target genes 
to activate the expression of a wide range of genes associated with 
key biological processes including metabolism, angiogenesis, cell 
differentiation, apoptosis and autophagy, for adaptation to hypoxia 
(Liu et al., 2012).
In addition to the physiological inducer of low oxygen, HIF can 
be activated by chemical agents that mimic or inhibit compo-
nents of the hypoxia signalling pathway, including Fe2+ substitutes 
(Wang & Semenza, 1993; Xi et al., 2004), Fe2+ chelators (Eltzschig 
et al., 2014), 2-oxoglutarate mimics (Chan et al., 2016; McDonough 
et al., 2005), inhibitors of PHDs (Chan et al., 2015; Chowdhury 
et al., 2013; Locatelli et al., 2017), and more recently, inhibitors 
of VHL (Buckley et al., 2012; Frost et al., 2016; Galdeano et al., 
2014; Soares et al., 2018). Pharmacological stabilisation of HIF 
could provide therapeutic benefit for many diseases including 
myocardial ischemia-reperfusion injury (Eckle et al., 2012; 
Hill et al., 2008; Rey et al., 2009), inflammatory bowel diseases 
(Biddlestone et al., 2015; Cummins et al., 2013; Marks et al., 
2015), anaemia-associated chronic kidney diseases (Macdougall, 
2008; Provenzano et al., 2016), wound healing (Albina et al., 
2001; Botusan et al., 2008) and assistance of organ transplantation 
(Cheng et al., 2010). Over the years, PHD inhibitors have entered 
clinical trials, with FG-4592 in clinical trial phase III for the 
treatment of anaemia associated with chronic kidney diseases 
(Provenzano et al., 2016). Recent studies have identified PHD 
inhibitors or the knockout of VHL as protective during mitochon-
drial dysfunction (Jain et al., 2016). VHL inhibitor VH298 has 
been demonstrated for the first time in vivo to accelerate healing 
and maturation of enthuses in rats (Qiu et al., 2018), highlighting a 
therapeutic potential of the inhibitor in wound healing.
Considering the pharmacological use and therapeutic potential 
of PHD inhibitors and the newly emerging VHL inhibitors, it is 
important to identify gene expression responses elicited by such 
agents. As such, we employed RNA-sequencing (RNA-seq) 
to determine the similarities and differences of the transcrip-
tional response under hypoxia, the inhibitor of PHD, IOX2 
(Chowdhury et al., 2013), as well as the VHL inhibitor VH032 
(Frost et al., 2016; Galdeano et al., 2014). We show that IOX2 
and VH032 mimic the hypoxia response and that these predomi-
nantly induce a HIF-dependent gene signature. On the other 
hand, hypoxia produces the broader transcriptional response 
amongst all the inducers used, with significant numbers of genes 
being induced and repressed.
Methods
Cell culture
Human cervix carcinoma cells HeLa (ATCC® CCL-2™) and 
human foreskin fibroblasts HFF (ATCC® SCRC-1041™) were 
obtained from the American Type Culture Collection (ATCC). 
All cells were propagated in Dulbecco’s Modified Eagle Medium 
(Sigma; 1992394) supplemented with 10% fetal bovine serum 
(Gibco; 10082147), 2 mM L-glutamine (Gibco; 25030024), 
50 units/mL of penicillin (Lonza) and 50 µg/mL streptomycin 
(Lonza; DE17-602E) at 37°C. Cells were routinely tested for 
mycoplasma contamination using MycoAlert kit from Lonza 
(LT07-218).
Treatments
For hypoxia induction, cells were incubated at 1% O2 in an 
InVIVO 300 hypoxia workstation (Ruskin Technologies). To 
prevent reoxygenation, cells were lysed for protein or RNA 
extraction in the hypoxia workstation. DMSO was used as vehi-
cle control for compound treatment. PHD inhibitors IOX2 and 
FG-4592 were purchased from from Sigma (SML0652) or 
Selleckchem (S2919) and Selleckchem (S1007), respectively. 
Drugs were added to cells for the indicated length of time. 
VHL inhibitors VH032 and VH298 were synthesised by Pedro 
Soares (Ciulli lab, University of Dundee) as previously described: 
VH032 (ligand 7 in Galdeano et al. (2014); compound 1 in 
(Soares et al., 2018) and VH298 (Frost et al., 2016). VH298 was 
also purchased from Sigma (SML1896).
RNA preparation for RNA-seq
HeLa cells were seeded in 35 mm dishes one day prior to 
treatments with 0.05% DMSO, hypoxia (1% O2), 250 µM 
IOX2, or 250 µM VH032 for 16 h. RNA was extracted using 
the RNeasy Mini Kit (Qiagen; 74104) according to manufac-
turer’s instruction. Genomic DNA was removed from RNA 
samples using RNase-free DNase from Qiagen (79254) as 
per manufacturer’s protocol. Experiments were performed in 
triplicates.
RNA-seq library preparation and sequencing
Library preparation and sequencing were performed by the 
University of Dundee Genome Sequencing Unit. The library was 
prepared using TruSeq Stranded Total RNA Library Preparation 
Kit with Ribo-ZeroTM Human/Mouse/Rat kit (Illumina; RS-122 
2201) to remove ribosomal RNA (rRNA). RNA ERCC ExFold 
RNA Spike-In Mix (Mix1 and Mix2) was distributed throughout 
the RNA-seq experiment according to manufacturer’s protocol 
(4456739, Thermo Scientific). Paired-end Illumina sequencing was 
performed on the NextSeq 500 platform.
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RNA-seq data analysis
The raw sequence reads from each replicate were aligned to the 
Ensembl human genome GRCh37 and ERCC sequence with 
STAR version 2.4.2a. The aligned reads were combined and 
number of reads for each gene was counted with subread- 
featureCounts pipeline version 1.4.6-p4 (Liao et al., 2014). The 
files were found to contain ribosomal DNA (rDNA) contamina-
tions, the majority of which were the following two mitochon-
drial DNA: ENSG00000211459 and ENSG00000210082 – which 
were removed manually. Differential gene expression analysis 
was performed by the R package edgeR (v3.24.1) according to 
its user guide (Robinson et al., 2010), and differentially 
expressed genes were identified at FDR of <0.05 and log2 fold 
change > 0.58.
Integrative analysis was performed manually in R (v1.1.453) 
to obtain lists of genes that overlap to publicly available 
datasets. Briefly, a list of differentially expressed genes upregu-
lated in hypoxia, IOX2, VH032 or in all three conditions was 
compared to publicly available data and overlapping genes were 
exported into excel sheet. Enrichment analysis of transcrip-
tion factors and chromatin binding proteins on our datasets was 
carried out using TFEA.ChIP (v1.2.2) according to its user 
guide (Puente-Santamaria & Del Peso, 2019). Gene set enrich-
ment analysis was performed using GSEA MSigDB online tool 
(Liberzon et al., 2011; Subramanian et al., 2005) for hallmark 
genes with FDR < 0.05 and p value < 0.05.
Sequence data are available from Gene Expression Omnibus 
GSE120675.
Quantitative real time-PCR (qRT PCR)
Total RNA extracted using the RNeasy Mini Kit (Qiagen) was 
reverse transcribed using the iScript™ cDNA Synthesis Kit 
(BIO RAD; 170-8891). SYBR green-based qRT-PCR was per-
formed in 96-well plate using iQ™ SYBR® green supermix 
(BIO-RAD; 1708880) in MX3005P qPCR platform (Strata-
gene/Agilent). Relative quantity or fold change comparing each 
treatment to DMSO control for the same gene within the rep-
licate (with the exception for CA9 in which fold changes were 
calculated comparing to hypoxia) were generated using the 
MxPro qPCR software (v4.10), based on the ΔΔCT method accord-
ing to its manual. mRNA level of β-Actin was used for normali-
sation. Results were shown as mean and SEM of a minimum 
of three independent experiments. Primers were designed and 
purchased from Invitrogen. Sequences of primers used are as 
follows: β-Actin_F, CCCAGAGCAAGAGAGG and β-Actin_R, 
GTCCAGACGCAGGATG; BNIP3_F, GCCCACCTCGCTCGCA-
GACAC and BNIP3_R, CAATCCGATGGCCAGCAAATGAGA; 
BNIP3L_F, GTGGAAATGCACACCAGCAG and BNIP3L_R, 
CTTGGGTGGAATGTTTTCGG; CA9_F, CTTTGCCAGAGTT-
GACAGG and CA9_R CAGCAACTGCTCATAGGCAC; 
FAM117B_F, CTCTTGCTGCACCGTATCTT and FAM117B_R, 
CATGCACTCTCTGTCTGTGTAG;GLUT3_F, CAATGCTCCT-
GAGAAGATCAAA and GLUT3_R, AAAGCGGTTGACGAA-
GAGT; HK2_F, AGCCCTTTCTCCATCTCCTT and HK2_R, 
AACCATGACCAAGTGCAGAA; IDH2_F, AGACCGACTTC-
GACAAGAATAAG and IDH2_R, GACTGCACATCTCCGT-
CATAG; JMJD1A_F, GTCAACTGTGAGGAGATTCCAGC and 
JMJD1A_R, AACTTCAACATGAATCAGTGACGG; JMJD2B_F, 
GGGGAGGAAGATGTGAGTGA and JMJD2B_R, GACG-
GCTTTTGGAGGGTAAT; JMJD2C_F, CGAGGTGGAAAGTC-
CTCTGAA and JMJD2C_R GGGCTCCTTTAGACTCCATGTAT; 
JMJD6_F, TGGCATGTTGTCCTCAATCT and JMJD6_R, 
TCTCCCTCTTACCGTCTTGT; NDRG1_F, GGAGTCCT-
TCAACAGTTTGG and NDRG1_R, CACCATCTCAGGGTT-
GTTTAG; PHD2_F, GAAAGCCATGGTTGC and PHD2_R, 
TGTCCTTCTGGAAAAATTCG; PHD3_F, ATCGACAGGCT-
GGTCCTCTA and PHD3_R, CTTGGCATCCCAATTCTTGT; 
RNF187_F, GGGTCTGTGGAAATCATGAGAA and RNF187_R, 
CAGCTTCTTGTAGTCGGTCAG
Immunoblotting
Cells were harvested using radio Immunoprecipitation assay 
(RIPA) lysis buffer (50 mM Tris pH 8, 150 mM NaCl, 0.1% 
(w/v) SDS, 1% (v/v) NP-40, 0.5% (w/v) sodium deoxycholate, 
5 mM NaF, 500 mM Na3VO4, and one tablet/10 mL Complete, 
mini, EDTA-free protease inhibitor [Roche; 11873580001]) and 
kept on ice for 15–30 min before centrifugation at 17,000 × g, 
4°C for using Heraeus™ Fresco™ 21 Microcentrifuge (Thermo 
Scientific) 10 min. The supernatant was collected and stored 
at –80°C. SDS PAGE and immunoblots were carried out using 
standard protocols (Frost et al., 2016).
The following primary antibodies were used for immunoblot-
ting (catalogue number, supplier, clonality, host species and dilu-
tion factor were included): HIF-1α (610958, BD Biosciences; 
monoclonal; mouse; 1:1000), β-Actin (66009-1-Ig, Protein-
tech; monoclonal; mouse; 1:10000), BNIP3 (ab10433, Abcam; 
monoclonal; mouse; 1:10000), BNIP3L (12396, Cell Signalling; 
monoclonal; rabbit; 1:1000), CA9 (NB100-417, Novus Biologi-
cals; polyclonal; rabbit; 1:1000), GLUT1 (12939, Cell Signal-
ling; monoclonal; rabbit; 1:1000), GLUT3 (LS-C176045, LSBio; 
polyclonal; mouse; 1:1000), HK2 (2867S, Cell Signalling; 
monoclonal; rabbit; 1:2000), JMJD1A (ABE195, Millipore; 
polyclonal; rabbit; 1:1000), JMJD2B (8639S, Cell Signalling; 
monoclonal; rabbit; 1:1000), JMJD2C (PA5-23065, Thermo 
Scientific; polyclonal; rabbit; 1:1000), NDRG1 (5196, Cell 
Signalling; polyclonal; rabbit; 1:1000), PHD2 (A300-322A, 
Bethyl Laboratories; polyclonal; rabbit; 1:1000).
Results
IOX2 and VH032 induce a similar transcriptional response 
profile, while hypoxia induces a broader response in cells.
The hypoxia inducible factors (HIFs) can be induced in a 
variety of different ways, from the physiological inducer of low 
oxygen, to the pharmacological inhibition of proteins involved in 
the HIF pathway, as well as by changes in alternative pathways 
such as transcription and translation (Ferreira et al., 2015; 
Moniz et al., 2015; Semenza, 2003).
To understand the similarities and differences between the tran-
scriptional responses to several HIF inducers, an unbiased 
high-throughput RNA-sequencing (RNA-seq) was performed. 
Human cervical cancer HeLa cells were exposed to 0.05% 
DMSO (vehicle control), hypoxia (1% O2), PHD inhibitor IOX2 
or VHL inhibitor VH032 for 16 hours prior to profiling for global 
transcriptomic analysis using RNA seq.
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Differential expression analysis of data collected from RNA-
seq showed that DMSO samples cluster together with weak 
correlation to the other treatments, whilst hypoxia, IOX2 
and VH032 conditions were grouped close to one another 
(Figure 1A–B). Furthermore, heatmaps generated using the top 
100 most differentially expressed (DE) genes in each experimen-
tal condition comparing to DMSO control showed that hypoxia 
(Figure 1C), VH032 (Figure 1D) and IOX2 (Figure 1E) displayed 
Figure 1. Differential gene expression analysis of RNA-seq results. (A) Heatmap of Pearson correlations among RNA-seq samples that 
have been normalised to their total counts. (B) Multidimensional scaling plot of RNA-seq data. The distance between two samples reflects 
the leading logFC of the corresponding samples. The leading logFC is the average (root mean square) of the 2000 largest absolute logFCs 
for genes between those two samples. (C–E) Heatmaps of log2 counts per million (logcpm) across all the samples using the top 100 most 
differentially expressed (DE) genes in (C) Hypoxia, (D) VH032, and (E) IOX2. The Pearson correlation was used to compute distances 
between genes and samples, and the clustering was performed using average linkage. Each column corresponds to a sample and each 
row corresponds to a specific gene. (F) Heatmaps of Pearson correlations between replicates of the same conditions. Each data had been 
normalised to their total counts. (G) Each dot represents a differentially expressed gene comparing the condition stated in the heading legend 
to DMSO vehicle control. Blue dots represent genes with increased expression (logFC > 0.58; to the right) or decreased expression (logFC 
< –0.58; to the left) at false discovery rate (FDR)<0.05. Blue triangles (present at –log10 FDR of 30) represent genes with logFC > 0.58 or 
< –0.58 and –log10 FDR > 30.
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Table 1. Comparison to reported hypoxia-inducible datasets.
Description of dataset Number of 
genes in the 
dataset
Number of upregulated genes Reference
Hypoxia 
(1133)
IOX2 
(827)
VH032 
(362)
Overlap 
(306)
Hypoxia-inducible in  
16 cell lines
259 115 92 69 64 (Ortiz-Barahona  
et al., 2010); 
Supporting data G
HeLa hypoxia-inducible 1141 129 100 61 55 (Mense et al., 2006); 
Supporting data H
MCF7 hypoxia-
inducible_Elvidge2006
246 75 53 45 42 (Elvidge et al., 2006); 
Supporting data I
MCF7 hypoxia-
inducible_Chan2016
1081 307 257 172 163 (Chan et al., 2016); 
Supporting data J
TOTAL 410 326 200 185
similar transcriptional profiles to each other and were notice-
ably distinct from the vehicle control DMSO. These observa-
tions are likely due to the activation of HIF pathway as the three 
treatments activate HIF. Correlation analysis heatmaps for each 
condition showed a strong correlation between 0.95 and 1 across 
replicates of the same experimental condition (Figure 1F), 
and replicates of each treatment cluster together in heatmaps 
of top 100 most DE genes (Figure 1C–E), demonstrating that 
replicates of each condition were similar and statistically close to 
each other.
To investigate and observe the differences in gene expression 
between treatments, volcano plots were generated (Figure 1G). 
Overall, hypoxia exposure induced the broadest transcriptional 
changes, followed by IOX2 and finally VH032 resulted in the 
narrowest profile (Figure 1G). Analysis revealed the presence 
of more than 2,000 genes that were differentially expressed at 
5% false discovery rate (FDR) in hypoxia, with similar num-
bers of genes being upregulated (1,133; Dataset 1 (Frost, 2019)) 
and downregulated (957; Dataset 1 (Frost, 2019) (Figure 1G)). 
Treatments of cells with IOX2 or VH032 induced mostly upreg-
ulation of genes (827 in IOX2 and 362 in VH032, Dataset 1 
(Frost, 2019)), and only 117 (IOX2; Dataset 1 (Frost, 2019)) 
and 33 (VH032; Dataset 1 (Frost, 2019)) genes were found to be 
repressed (Figure 1G).
To investigate the nature of the transcriptional data we obtained, 
we performed integrative analysis of our hypoxia dataset with 
publicly available hypoxia-inducible gene sets (Table 1, Data-
set 1 (Frost, 2019)). Overlap analysis showed that 36% (410 out 
the 1,133) genes upregulated in hypoxia were present in at least 
one of the reported datasets, with 115 genes found upregulated 
in 16 cell lines (Ortiz-Barahona et al., 2010), 129 genes in 
HeLa dataset (Mense et al., 2006), as well as 75 and 307 genes 
in in MCF7 cells (Chan et al., 2016; Elvidge et al., 2006). This 
analysis confirmed the cell-specific and time-dependent tran-
scriptional responses elicited by hypoxia exposure in cells. We 
also compared our IOX2 and VH032 datasets with the previously 
reported gene sets to assess the extent to which genes upregu-
lated in IOX2 or VH032 also hypoxia-inducible. We identified 
a large portion of genes upregulated by IOX2 (39%; 325 out of 
827) or VH032 (56%; 200 out of 362) to be present in at least 
one of these reported hypoxia datasets (Table 1, Dataset 1 
(Frost, 2019)). This analysis showed that VH032 is predomi-
nantly regulating hypoxia-inducible genes, consistent with 
specific on-target effects on VHL (Frost et al., 2016).
Genes upregulated in hypoxia, IOX2 and VH032 are HIF-
dependent
Comparative analysis of upregulated genes distinctly showed that 
the majority of VH032-induced genes (~87%; 315 out of 362) 
are also upregulated by hypoxia (Figure 2A). On the other hand, 
IOX2-induced genes are only partially shared with the hypoxia 
signature (~68%; 559 out of 827). Notably, nearly all of the 
VH032-induced genes (93%) are shared with IOX2. Overall, 306 
genes are upregulated in all of the three experimental conditions 
(Figure 2A; Dataset 1 (Frost, 2019)).
Given that hypoxia, IOX2, and VH032 all induce HIF transcrip-
tional activity, we next investigated the extent to which these 
306 overlapped genes upregulated in all three conditions were 
regulated by HIF transcription factors. We performed integra-
tive analysis on the overlapped genes with reported datasets of 
validated HIF-1 targets (Benita et al., 2009), as well as HIF-1α 
and HIF-2α binding sites under hypoxia in MCF7 (Mole et al., 
2009) and HepG2 (Smythies et al., 2019) identified in 
ChIP-sequencing experiments (Table 2, Dataset 1 (Frost, 2019)). 
This analysis revealed that 132 out of these 306 (43%) genes were 
HIF-dependent (Table 2, Dataset 1 (Frost, 2019)). A total of 33 
out of the 306 shared genes was present in the list of 93 validated 
HIF-1 target genes (Dataset 1 (Frost, 2019)). Analysis using 
MCF7 ChIP-seq dataset showed that 62 (20%) and 33 (11%) of 
the 306 upregulated genes contained HIF-1α and HIF-2α binding 
sites, respectively (Dataset 1 (Frost, 2019)). A higher level of 
overlap was observed when we analysed the HepG2 ChIP-seq 
dataset, revealing that 90 out of the 306 genes (29%) contained 
either HIF-1α or HIF-2α binding sites (Dataset 1 (Frost, 2019)).
We next utilised TFEA.ChIP that exploits publicly available 
ChIP-seq datasets to perform enrichment analysis of transcription 
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Figure 2. Analysis of differential expressed genes obtained by RNA-seq. (A) Venn diagrams showing the number of genes upregulated 
(logFC > 0.58) or downregulated (logFC < –0.58) with false discovery rate (FDR) < 0.05 in hypoxia, IOX2 and VH032 treated cells compared 
to DMSO control. (B) Transcription factor enrichment analysis using TFEA.ChIP showing binding site enrichment for genes commonly 
upregulated in hypoxia, IOX2 and VH032. The graph represents the adjusted p value (-log10 FDR) and the log-odds ratio (Log2.OR) for the 
association of ChIP datasets. (C–D) Gene set enrichment analysis (GSEA) MsigDB showing significant enrichment of gene set signatures for 
(C) downregulated and upregulated genes in hypoxia, IOX2 or VH032 and (D) genes upregulated in hypoxia, IOX2 and VH032 at 5% FDR.
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Table 2. Hypoxia-inducible factors (HIF) dependency analysis. Our datasets were 
compared to reported list of validated HIF target genes and ChIP-seq datasets of HIF-1α and 
HIF-2α binding sites.
Description of 
dataset
Number of 
genes in the 
dataset
Number of upregulated genes Reference
Hypoxia 
(1133)
IOX2 
(827)
VH032 
(362)
Overlap 
(306)
HIF-1 target 93 49 39 36 33 (Benita et al., 2009); 
Supporting data L
HIF-1α binding 
sites (MCF7)
356 101 86 65 62 (Mole et al., 2009); 
Supporting data M
HIF-2α binding 
sites (MCF7)
301 65 40 35 33 (Mole et al., 2009); 
Supporting data N
HIF-1α binding 
sites (HepG2)
1516 153 137 94 90 (Smythies et al., 2019); 
Supporting data O
HIF-2α binding 
sites (HepG2)
1528 173 153 95 90 (Smythies et al., 2019); 
Supporting data P
TOTAL 274 215 141 132
factors and chromatin binding proteins on our dataset of 
commonly upregulated genes (Puente-Santamaria & Del Peso, 
2019). Result demonstrated HIF-dependency of the 306 commonly 
induced genes as HIF transcription factors were significantly 
enriched. (Figure 2B).
Taken together, these comparative analyses demonstrate the 
level of HIF dependency for genes upregulated by both hypoxia, 
IOX2 and VH032.
To investigate the cellular processes induced by hypoxia, IOX2 
or VH032, gene set enrichment analysis (GSEA) was per-
formed according to the molecular signature database (MSigDB) 
(Subramanian et al., 2005; Liberzon et al., 2011). All treatments 
induced a similar set of enrichment for genes involved in the 
“cellular response to hypoxia”, “glycolysis”, “epithelial-mesen-
chymal transition”, “mTORC1 signalling” and “NF-κB signalling” 
(Figure 2C). However, genes repressed by the different treat-
ments mapped to quite diverse cellular pathways and responses 
(Figure 2D). Furthermore, the group of 306 commonly upregulated 
genes in all three conditions was enriched with genes found in 
these same hallmarks (Figure 2B), primarily hypoxia and 
glycolysis. Altogether, data indicates that the three treatments 
activate mainly the hypoxia signalling pathway via HIF transcrip-
tion factors.
RNA-seq validation, genes commonly upregulated in 
hypoxia, IOX2 and VH032
To validate data obtained from the RNA-seq analysis, we selected 
several known HIF target genes amongst the 306 upregulated 
genes (BNIP3, BNIP3L, CA9, GLUT3 [SLC2A3], HK2, JMJD1A 
[KDM3A], JMJD2B [KDM4B], JMJD2C [KDM4C], NDRG1, 
PHD2 [EGLN1], and PHD3 [EGLN3]) to perform quantita-
tive real-time PCR (qRT PCR) (Figure 3A). We replaced IOX2 
with the PHD inhibitor FG-4592 that is currently in clinical 
trial phase III (Provenzano et al., 2016). Furthermore, VH032 
was replaced with the more potent VHL inhibitor VH298 
(Frost et al., 2016). After exposure to 16 hours of hypoxia, FG-
4592 (50 µM) or VH298 (100 µM), mRNA levels of these genes 
increased significantly with similar induction profiles in both 
HeLa (Figure 3B) and HFF cells (Figure 3C). Hypoxia showed the 
strongest induction profiles in nearly all genes examined in both 
cell lines (Figure 3). Moreover, the changes in transcript levels 
were also reflected at the protein level (Figure 4). Accumula-
tion of the products of these HIF target genes, as well as GLUT1 
protein, another HIF target which we had previously character-
ised at mRNA level (Frost et al., 2016), was detected following 
24 hour treatment of hypoxia, VH298 or FG-4592 in HeLa and 
HFF cells (Figure 4A). In both cell lines, the three treatments 
induced similar levels of protein expression for the majority of 
HIF targets assessed, with NDRG1 being the most prominent 
in hypoxia. FG-4592 was the strongest inducer of CA9 in HeLa 
cells and BNIP3 in both cell lines (Figure 4A). The difference 
in the levels these genes and therefore proteins were increased 
could be due to the single time point used; particularly since 
the three conditions act on the HIF pathway at different stages 
(1% oxygen level limits the activities of PHD and FIH, FG 
4592 inhibits PHDs and VH298 inhibits VHL downstream of 
hydroxylation by PHD). To address this question, we performed 
a time course analysis for the three inducers and investigated 
protein levels of the different HIF-target genes (Figure 4B). This 
revealed that hypoxia is the strongest inducer of all the proteins we 
have analysed at the 24 h post-treatment time point.
RNA-seq validation, genes solely upregulated in hypoxia 
and IOX2.
Hypoxia and IOX2 share the larger overlap of 252 upregulated 
genes that are not found in VH032 (Dataset 1 (Frost, 2019)). On 
the other hand, there are 30 upregulated common genes between 
IOX2 and VH032, but not hypoxia, as well as the 9 common upreg-
ulated genes in hypoxia and VH032, but not IOX2 (Figure 2A). 
As recent studies have revealed additional targets of PHD 
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Figure 3. Validation of genes with increased transcript level in hypoxia, IOX2 and VH032. (A) Bar plot showing log2FC according to data 
obtained from RNA seq analysis of known HIF target genes in hypoxia, IOX2 and VH032. (B) HeLa and (C) HFF cells were treated with 0.05% 
DMSO (vehicle control), 1% O2 (hypoxia), 100 µM VH298 and 50 µM FG-4592 for 16 h prior to mRNA extraction. The graphs show relative 
mRNA transcripts normalised to actin mRNA levels. The mean + SEM were determined from three independent experiments. Two-tailed 
student t-test analysis was performed * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 and ns: P>0.05.
Page 9 of 17
Wellcome Open Research 2019, 4:17 Last updated: 13 FEB 2019
Figure 4. Analysis of protein levels of genes with increased transcription in hypoxia, IOX2 and VH032. HIF targets were increased 
in hypoxia, VH298 and FG-4592. 0.05% DMSO (vehicle control), 1% O2 (hypoxia), 100 µM VH298 and 50 µM FG-4592 were introduced to 
(A) HeLa or HFF for 24 hours and (B) HeLa for indicated time. Protein levels were analysed by immunoblotting using antibodies against 
indicated proteins, with β-Actin as loading control. The blots shown are representative of three independent experiments. * indicates longer 
exposure.
enzymes, we analysed several of these 252 genes to determine 
whether PHDs induce transcriptomic changes independent of 
HIF activity. We selected four genes, including IDH2, RNF187, 
FAM117B and JMJD6 from the list of 252 genes upregulated solely 
in hypoxia and IOX2 for validation by qRT-PCR. The results, 
however, show that mRNA levels of these genes increased sig-
nificantly in all the three conditions, including the VHL inhibitor 
VH298 (Figure 5A–B). Analysis of the RNA-seq data revealed 
an increase in each of the four genes in VH032 treatment (Data-
set 1 (Frost, 2019)); however, this level was insufficient to reach 
the threshold of log2FC of 0.58 (Figure 5C). As VH298 is more 
potent than VH032 (Frost et al., 2016), VH298 is predicted to 
induce a more pronounced effect on gene expression of target 
genes. It is likely that the 252 upregulated genes were found to be 
enriched solely in hypoxia and IOX2, are also induced by the more 
potent VHL inhibitor VH298, indicative of a common regulator 
between these treatments. Furthermore, these 252 genes showed 
significant enrichment of genes involved in pathways similar to 
commonly upregulated genes (Figure 5D, Figure 2B), as well as 
enriched for HIF binding sites (Figure 5E).
Discussion
Here, we used high-throughput RNA-sequencing to investi-
gate the similarity and differences in the transcriptional response 
towards hypoxia, the PHD inhibitor IOX2 and the VHL inhibi-
tor VH032. Although genome-wide expression profiling 
comparing hypoxia and IOX2 has previously been reported 
(Chan et al., 2016), to our knowledge this is the first report of 
gene expression profiling comparing side-by-side responses 
of hypoxia and PHD inhibitors to VHL inhibitors. These three 
treatments activate the HIF transcription factors, but via limiting 
or inhibiting different components of the hypoxia signalling 
pathway.
Our results provide insights into the effects of inhibiting PHD 
or VHL on HIF target genes, and unique responses in each con-
dition. While hypoxia induced the broadest transcriptional 
changes, IOX2 and VH032 possessed similar transcriptional 
responses. The three conditions upregulated a common group of 
306 genes (Dataset 1 (Frost, 2019)), the majority of which are 
regulated by HIF transcription factors (Figure 2B). From this 
list, we were able to validate a number of known HIF targets in 
HeLa and HFF cells (Figure 3, Figure 4). Furthermore, we also 
found that 132 of these 306 genes were either validated HIF 
targets or possess HIF-1α/2α binding sites (Dataset 1 (Frost, 
2019)). This suggest that while the 132 genes are likely HIF 
targets, the remaining 174 genes (Dataset 1 (Frost, 2019)) could 
also be potential novel HIF targets.
As hypoxia, VH032 and IOX2 activate HIF, our datasets of genes 
induced in these conditions are predominantly enriched for HIF 
transcription factors (Figure 6A–C). Beside gene activation, 
hypoxia also promotes gene repression. Our results show that 
hypoxia downregulated a significantly larger number of genes 
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Figure 5. RNA seq validation of genes solely upregulated in hypoxia and IOX2, but not VH032. (A) HeLa and (B) HFF cells were treated 
with 0.05% DMSO (vehicle control), 1% O2 (hypoxia), 100 µM VH298 and 50 µM FG-4592 for 16 h prior to mRNA extraction. The graphs 
show relative mRNA transcripts normalised to actin mRNA levels. The mean + SEM were determined from three independent experiments. 
Two-tailed student t-test analysis was performed * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 and ns: P>0.05. (C) Table showing log2FC according 
to data obtained from RNA-seq analysis of known HIF target genes in hypoxia and IOX2, but not VH032. (D) Gene set enrichment analysis 
(GSEA) MsigDB showing significant enrichment of gene set signatures for genes upregulated in hypoxia and IOX2, but not found in VH032 
at 5% false discovery rate (FDR). (E) Transcription factor enrichment analysis using TFEA.ChIP showing binding site enrichment for genes 
upregulated in hypoxia and IOX2, but not B032. The graph represents the adjusted p value (-log10 FDR) and the log-odds ratio (Log2.OR) 
for the association of ChIP datasets.
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Figure 6. Transcription factor enrichment analysis. Transcription factor enrichment analysis using TFEA.ChIP showing binding site 
enrichment for genes upregulated in (A) VH032, (B) IOX2 and (C) hypoxia, or (D) downregulated in hypoxia. The graph represents the 
adjusted p-value (-log10 false discovery rate (FDR)) and the log-odds ratio (Log2.OR) for the association of ChIP datasets.
compared to IOX2 and VH032 (Figure 1G). Various mechanisms 
of transcriptional repression in hypoxia are known (Batie et al., 
2018) and one mechanism includes the activity of SIN3A. A 
recent bioinformatics study showed that SIN3A and a number of 
its co-repressors including HDAC1 were overrepresented in 
the proximity of genes transcriptionally repressed by hypoxia 
(Tiana et al., 2018). Consistent to the reported roles of SIN3A 
and HDAC1 in hypoxia signalling (Batie et al., 2018), we 
found that our datasets of downregulated genes in response to 
hypoxia were enriched for SIN3A and HDAC1 (Figure 6D). The 
transcription factor REST was also enriched in genes repressed 
in hypoxia (Figure 6D) and this is consistent to a recent finding 
that REST transcriptionally repressed genes in hypoxia (Cavadas 
et al., 2016).
Geneset enrichment analysis suggests that hypoxia, VH032 and 
IOX2 commonly upregulated genes enriched for NF-κB signal-
ling (Figure 2B). NF-κB is a transcription factor that has been 
shown to respond to cellular stress, including hypoxia and PHD 
inhibition (Cummins et al., 2006). Under hypoxia, NF-κB is 
activated and induces increased angiogenesis and decreased 
apoptosis (D’Ignazio & Rocha, 2016).
Overall, we reveal for the first time a comparison of genome- 
wide gene expression analysis of HIF activators, including 
the physiological inducer hypoxia, and small molecule inhibi-
tors of PHD enzymes and VHL. Understanding the differential 
regulation of genes in response to the three conditions will 
help to determine the functions of PHD and VHL in hypoxia 
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signalling, as well as revealing novel HIF-dependent and 
–independent genes. Furthermore, considering the potential 
use of PHD inhibitors that are currently in clinical trials and the 
potential of VHL inhibitors for therapeutic benefits, our report 
contributes to the further understanding of the pharmacological 
effects of these inhibitors.
Data availability
Underlying data
Underlying data for this study is available from Open Science 
Framework (OSF)
OSF: Dataset 1. RNA-seq analysis of PHD and VHL inhibitors 
reveals differences and similarities to the hypoxia response https://
doi.org/10.17605/OSF.IO/4A6TG (Frost, 2019)
Licence: CC0 1.0 Universal
Legend for file Supporting data.xlsx
A – List of genes upregulated in hypoxia with FDR ≤ 5% and 
logFC ≥ 0.58
B – List of genes downregulated in hypoxia with FDR ≤ 5% and 
logFC ≤ –0.58
C – List of genes upregulated in IOX2 with FDR ≤ 5% and 
logFC ≥ 0.58
D – List of genes upregulated in VH032 with FDR ≤ 5% and 
logFC ≥ 0.58
E – List of genes downregulated in IOX2 with FDR ≤ 5% and 
logFC ≤ –0.58
F – List of genes downregulated in VH032 with FDR ≤ 5% and 
logFC ≤ –0.58
G – List of hypoxia-inducible genes conserved across 16 cell 
lines (Ortiz-Barahona et al., 2010)
H – List of hypoxia-inducible genes in HeLa (Mense et al., 2006)
I – List of hypoxia-inducible genes in MCF7 (Elvidge et al., 2006)
J – List of hypoxia-inducible genes in MCF7 (Chan et al., 2016)
K – List of genes commonly upregulated in hypoxia, IOX2, and 
VH032. Genes that are found in HIF 1 validated target genes 
(K), HIF 1α (L) and HIF 2α (M) binding sites in MCF7, as well 
as HIF 1α (N) and HIF 2α (O) in HepG2 are highlighted in 
yellow under column C-G, respectively
L – HIF 1 validated target genes (Benita et al., 2009)
M – List of HIF-1α binding sites identified in MCF7 (Mole 
et al., 2009)
N – List of HIF-2α binding sites identified in MCF7 (Mole 
et al., 2009)
O – List of HIF-1α binding sites identified in HepG2 (Smythies 
et al., 2019)
P – List of HIF-2α binding sites identified in HepG2 (Smythies 
et al., 2019)
Q – List of genes solely upregulated in hypoxia and IOX2, but not 
in VH032. However, LogFC value in VH032 is stated in column 
C, together with its p-Value (column D) and FDR (column E)
Sequence data from this study has been uploaded to Gene 
Expression Omnibus, accession number: GSE120675
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In this manuscript, Frost   have used high-throughput RNA sequencing to compare the cellularet al
transcriptional response to hypoxia with that of pharmacologic HIF hydroxylase or pVHL inhibition. Of
interest, hypoxia was a more potent stimulus of gene expression and repression than either hydroxylase
or pVHL inhibition. Given the recent introduction of pharmacologic targeting of the HIF hydroxylases  into
clinical medicine, understanding the cellular consequences of exposure to these agents in terms of global
gene expression (while already studied to some degree) is of continuing interest. The manuscript is well
written, addresses a clear and interesting hypothesis and delivers clear and important data. The
experiments are controlled and appear to be well carried out. The introduction includes a nice up to date
review of the pharmacology of the HIF pathway.
 
Specific Comments:
 
The authors should discuss the choice of IOX2 as a pharmacologic hydroxylase inhibitor for the
transcriptomic aspect of the study. What was the rationale of choosing this inhibitor over some of the
more commonly used and well characterized agents such as DMOG. Furthermore, the authors should
explain why the use of IOX2/VH032 was changed for FG-4592/VH298 for the RT-PCR validation studies
(would it not have made more sense to stick with the same compound).
 
It should be made clear why Hela cells and not a more physiologically relevant cell line were used for the
transcriptomic experiments. As these studies involve pharmacologic and hypoxic treatments, could
primary cells not have been used? Hela cells carry many chromosomal abnormalities and have limited
relevance to normal cell function.  This limitation should be discussed.
 
In Figure 1, it would be good to demonstrate (e.g. by western blot or HRE-liuciferase reporter assay or
both) the distinct temporal profile of HIF-1 and HIF-2  expression/activity elicited by the three treatments in
Hela cells over the 16 hour time course of exposure. It is possible that these treatments (due to their
differential mechanisms) elicit quite different temporal changes in HIF expression which may be of
relevance to the genes expressed.
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Frost et al examine how HIF transcriptional responses vary depending on the mode of HIF activation –
hypoxia versus inhibition of HIF-α degradation. Using RNAseq the authors find that hypoxia, PHD
inhibition or VHL inhibition activate the same HIF dependent genes but with some differences, principally
relating to gene suppression observed in hypoxia. The quality of the data is high and the experiments are
well presented. The results substantiate findings in previous reported studies and provide a very useful
dataset of hypoxia and/or HIF responsive genes. In addition, they demonstrate a clear difference between
the effect of hypoxia on gene repression compared to pharmacological stabilisation of HIF-α. Overall,
these findings will be of significant interest to many researchers within the field.
 
I have only one minor comment regarding the relative stabilisation of HIF-α in response to the different
treatments used. The RNAseq analysis was performed on cells treated for 16 hr with 1% oxygen, 250 μM
IOX2 or 250 μM VH032. Could the authors comment on the level of HIF-α stabilisation in response to
these different treatments? Figure 4B suggests that HIF-1α stabilisation varies over time in a distinct
manner with pharmacological inhibition compared to hypoxia. Are similar findings observed for IOX2 and
VH032? It would also be helpful if the authors could comment on how HIF-2α may vary following these
different treatments.
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